Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference
Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference
LONDON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024 at 9:35 a.m. Eastern Time.
倫敦，2024年11月26日（GLOBE NEWSWIRE）——基尼克薩製藥國際有限公司（納斯達克股票代碼：KNSA）今天宣佈，管理層將在美國東部時間2024年12月3日星期二上午9點35分參加第七屆Evercore ISI HealthConx年度會議的爐邊談話。
A live webcast of Kiniksa's presentation will be accessible through the Investors section of the company's website at . A replay of the event will also be available on Kiniksa's website within approximately 48 hours after the event.
Kiniksa演講的網絡直播可通過該公司網站的 「投資者」 部分觀看。該活動的重播也將在活動結束後的大約48小時內在Kiniksa的網站上公佈。
About Kiniksa
Kiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa's immune-modulating assets are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit .
關於 Kiniksa
Kiniksa是一家處於商業階段的生物製藥公司，專注於發現、收購、開發和商業化治療藥物，以幫助患有虛弱性疾病、醫療需求嚴重未得到滿足的患者。Kiniksa的免疫調節資產基於強有力的生物學原理或經過驗證的機制，針對一系列未得到充分治療的心血管和自身免疫疾病，並提供了差異化的潛力。欲了解更多信息，請訪問。
Every Second Counts!
每一秒都很重要！
Kiniksa Investor Contact
Jonathan Kirshenbaum
(781) 829-3949
jkirshenbaum@kiniksa.com
Kiniksa 投資者聯繫方式
喬納森·基爾申鮑姆
(781) 829-3949
jkirshenbaum@kiniksa.com
Kiniksa Media Contact
Tyler Gagnon
(781) 431-9100
tgagnon@kiniksa.com
Kiniksa 媒體聯繫人
泰勒·加格農
(781) 431-9100
tgagnon@kiniksa.com
